Value of Midtreatment 18F-FDP PET in Monitoring Response to Therapy and Prediction Outcome in Lymphoma

张红宇,孟庆祥,柳金,庞丽萍,王钧,许蕾,冯佳,张文丽,张倩,孙丽华,钟凤鸾,徐海婵,虞积仁
DOI: https://doi.org/10.3969/j.issn.1008-6358.2009.02.050
2009-01-01
Abstract:Objective:To evaluate midtreatment 18F-FDP PET in monitoring response to therapy and prediction outcome in Lymphoma.Methods:Retrospective analysis forty-three patients with lymphoma who underwent FDG-PET scan after four cycles of chemotherapy, it was also compared with computed tomography(CT),B ultrasonic and bone marrow biopsy to investigate lymph node/extranodal manifestations. Results:After four cycles of chemotherapy,15 patients had positive FDG-PET and all of them progressed or relapsed, 9 of 26 patients had positive CT or B ultrasonic progressed, 6 patients with FDG-PET -negative but CT-positive underwent second biopsy and pathologic result show no lymphoma evidences. Survival analyses showed midtreatment 18F-FDP PET-positive was independent risk factors of disease progression.Conclusion: Midtreatment 18F-FDP PET is a sensitive and specific technique in detecting residual masses of lymphoma and in assessment to therapy, midtreatment 18F-FDP PET is a strong and independent predictor of progression-free survival.
What problem does this paper attempt to address?